Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (261-270 of 308) with videos related to

Pageof 31
Sort By:
Annals of the Rheumatic Diseases|May 20, 2009
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritisLilian H D van Tuyl, Maarten Boers, Willem F Lems, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 12, 2022
[<sup>18</sup>F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiographyJerney de Jongh, Nicki J F Verweij, Maqsood Yaqub, et al.
Age and Ageing|July 29, 2021
Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trialsThomas Buttgereit, Andriko Palmowski, Noah Forsat, et al.
Seminars in Arthritis and Rheumatism|September 21, 2021
The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2Lara J Maxwell, Dorcas E Beaton, Maarten Boers, et al.
Annals of the Rheumatic Diseases|October 15, 2020
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working groupSabrina Mai Nielsen, Marianne Uggen Rasmussen, Maarten Boers, et al.
Helicobacter|September 1, 2007
Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trialHelena T J I de Leest, Kirsti S S Steen, Willem F Lems, et al.
The Journal of Rheumatology|August 13, 2009
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkersSilje W Syversen, Robert Landewe, Désirée van der Heijde, et al.
The Journal of Rheumatology|January 17, 2019
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT InitiativeSabrina M Nielsen, Peter Tugwell, Maarten P T de Wit, et al.
The Journal of Rheumatology|August 3, 2017
Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016Linda A Rasch, Maarten Boers, Catherine L Hill, et al.
Current Medical Research and Opinion|December 15, 2010
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RAJosef S Smolen, Maarten Boers, Eric C Abadie, et al.
Pageof 31

Showing results (261-270 of 308) with videos related to

Sort By:
Pageof 31
Annals of the Rheumatic Diseases|May 20, 2009
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritisLilian H D van Tuyl, Maarten Boers, Willem F Lems, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 12, 2022
[<sup>18</sup>F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiographyJerney de Jongh, Nicki J F Verweij, Maqsood Yaqub, et al.
Age and Ageing|July 29, 2021
Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trialsThomas Buttgereit, Andriko Palmowski, Noah Forsat, et al.
Seminars in Arthritis and Rheumatism|September 21, 2021
The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2Lara J Maxwell, Dorcas E Beaton, Maarten Boers, et al.
Annals of the Rheumatic Diseases|October 15, 2020
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working groupSabrina Mai Nielsen, Marianne Uggen Rasmussen, Maarten Boers, et al.
Helicobacter|September 1, 2007
Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trialHelena T J I de Leest, Kirsti S S Steen, Willem F Lems, et al.
The Journal of Rheumatology|August 13, 2009
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkersSilje W Syversen, Robert Landewe, Désirée van der Heijde, et al.
The Journal of Rheumatology|January 17, 2019
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT InitiativeSabrina M Nielsen, Peter Tugwell, Maarten P T de Wit, et al.
The Journal of Rheumatology|August 3, 2017
Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016Linda A Rasch, Maarten Boers, Catherine L Hill, et al.
Current Medical Research and Opinion|December 15, 2010
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RAJosef S Smolen, Maarten Boers, Eric C Abadie, et al.
Pageof 31